EcoDrugPlus

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOTSG00005011907
Gene Symbol: PIM3
1 Cross references
166 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOTSG00005022232
Gene Symbol: RAF1
1 Cross references
201 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOTSG00005011868
Gene Symbol: RAF1
3 Cross references
201 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSOTSG00005010728
Gene Symbol: ROCK2
1 Cross references
219 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSOTSG00005005941
Gene Symbol: ROCK2
1 Cross references
219 Possible Orthologues:

Rho-Associated, Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSOTSG00005029833
Gene Symbol: ROCK1
1 Cross references
206 Possible Orthologues:

Sem1 26s Proteasome Subunit

Ensembl ID : ENSOTSG00005013788
Gene Symbol: SEM1
1 Cross references
149 Possible Orthologues:

Sem1 26s Proteasome Subunit

Ensembl ID : ENSOTSG00005004824
Gene Symbol: SEM1
1 Cross references
150 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSOTSG00005026474
Gene Symbol: SRC
1 Cross references
186 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSOTSG00005031488
Gene Symbol: SRC
3 Cross references
186 Possible Orthologues:

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSOTSG00005004524
Gene Symbol: LOC112215283
3 Cross references
199 Possible Orthologues:

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSOTSG00005016349
Gene Symbol: LOC112226882
2 Cross references
150 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).